Tracking quality of life during prostate cancer treatment

April 16, 2018 by Anna Williams, Northwestern University
cancer
Killer T cells surround a cancer cell. Credit: NIH

Patients with advanced prostate cancer who received more intensive treatment experienced worse quality of life three months after treatment, but a better quality of life in the long term, compared to those on standard therapy, according to a new Northwestern Medicine study.

The findings were published in the Journal of Clinical Oncology.

"Treatment of prostate cancer is far more than just treating a cancer—it's treating a person," said first author Alicia Morgans, MD, MPH, associate professor of Medicine in the Division of Hematology and Oncology, and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. "That means we need to truly understand what men with prostate cancer experience—both due to the disease and due to the treatments we prescribe. If we don't specifically ask questions about of in our studies, we won't have be able to support men and their families as they go through ."

Prostate cancer is one of the most commonly diagnosed cancers in American men. For patients with an advanced form of the disease called metastatic hormone-sensitive prostate cancer (mHSPC), hormone therapy has long been the backbone of treatment.

More recently, a landmark clinical trial called E3805 demonstrated that patients with mHSPC on hormone therapy who also receive a chemotherapy drug called docetaxel live significantly longer than those who undergo hormone therapy alone.

But it was not known how quality of life might be affected in men receiving docetaxel and hormone therapy, versus those receiving the standard treatment alone. Understanding quality of life in patients with prostate cancer is especially important, the authors note, since is incurable and commonly affects older men with comorbidities.

In the current study, patients in the E3805 clinical trial randomized to each treatment group also completed quality of life assessments. The 790 participants reported measures of quality of life—including physical, functional and emotional well-being—at baseline and at three-month intervals for up to a year after treatment.

The investigators found that at three months, patients who received chemotherapy in addition to hormone therapy reported significantly worse quality of life. However, at one year, the group reported significantly higher quality of life measures, compared to those who received alone.

"In other words, paying a bigger price up front is probably worth it in the long run, for the right patients," Morgans said.

The authors note that the findings from the study—the first comparison of quality of life in this population—will be critical in helping patients and providers make more informed decisions about treatment for advanced prostate .

In the trial, the benefit of more intensive treatment appeared to be biggest for patients with high-volume disease—a larger amount of metastatic —although this is still being confirmed in additional , Morgans added.

Explore further: Treatment extends life for men with prostate cancer

More information: Alicia K. Morgans et al. Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer, Journal of Clinical Oncology (2018). DOI: 10.1200/JCO.2017.75.3335

Christopher J. Sweeney et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer, New England Journal of Medicine (2015). DOI: 10.1056/NEJMoa1503747

Related Stories

Treatment extends life for men with prostate cancer

June 1, 2014
A new treatment has been shown to extend the lifespans of men with advanced prostate cancer by as much as one year, researchers said Sunday.

Evaluating quality of life after kidney cancer treatments

February 19, 2018
Patients with an advanced form of kidney cancer had similar quality of life outcomes taking a drug called cabozantinib as those who received the standard treatment, everolimus, according to a new Northwestern Medicine study. ...

Combo treatment may boost survival with advanced prostate cancer

August 6, 2015
(HealthDay)—Chemotherapy at the start of hormone therapy can extend the lives of men with prostate cancer that has spread beyond the gland, a new study finds.

Adding chemotherapy to standard prostate cancer treatment may extend life expectancy

May 14, 2015
New research led by the University of Warwick shows newly diagnosed advanced prostate cancer patients who received the chemotherapy drug docetaxel with standard hormone therapy lived ten months longer on average, compared ...

New treatment regimen extends life for some men with recurrent prostate cancer, study finds

February 1, 2017
Adding hormonal therapy to radiation treatment can significantly improve the average long-term survival of men with prostate cancer who have had their prostate gland removed, according to a new Cedars-Sinai study published ...

Recurrence of prostate cancer could be reduced thanks to exciting new discovery

September 5, 2017
Ground breaking research could reduce the recurrence of prostate cancer in males, a new study in the journal Nature Communications reports.

Recommended for you

Study finds gut microbiome can control antitumor immune function in liver

May 24, 2018
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. Their study, published May 25 in Science, was led by researchers in the Center for Cancer Research (CCR) at the National ...

Low-fat diet tied to better breast cancer survival

May 24, 2018
(HealthDay)—Breast cancer patients who adopted a low-fat diet were more likely to survive for at least a decade after diagnosis, compared to patients who ate fattier fare, new research shows.

By forming clots in tumors, immune cell aids lung cancer's spread

May 24, 2018
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation ...

A cascade of immune processes offers insights to triple-negative breast cancer

May 24, 2018
Cancer is crafty. To survive and thrive, tumors find a way of thwarting our body's natural systems.

Cancer cells co-opt pain-sensing 'wasabi receptor' to survive oxidative stress

May 24, 2018
Anyone who's taken a bite of a sandwich with too much spicy mustard or a piece of sushi with too much wasabi can attest to the tear-inducing sensation these condiments can cause. These loud warnings to the nervous system ...

Tumor cells evade death through in extremis DNA repair

May 24, 2018
Greater knowledge of the mechanisms that contribute to the survival of tumour cells is key to vanquishing them. The study published today in the journal Cancer Cell, headed by Angel R. Nebreda, ICREA researcher at the Institute ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.